Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.30 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380101 | 0.81 | PTGS1 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL19755664 | 0.81 | PTGS1 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL19755665 | 0.81 | PTGS1 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL21100961 | 0.81 | PTGS1 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL16373137 | 0.81 | PTGS1 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL24904230 | 0.80 | KDM4E (0.36) | CHRNB4CHRNA3 | |
| SCHEMBL21100739 | 0.80 | CHRNB4 (0.34) | CHRNB4CHRNA3 | |
| SCHEMBL18347952 | 0.78 | TAS1R3 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL621014 | 0.78 | TAS1R3 (0.38) | CHRNB4CHRNA3CNR1CNR2 | |
| SCHEMBL15247217 | 0.75 | CHRNB4 (0.54) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | CHRNB4 4382/4885CHRNA3 4269/4885ACVR1 1917/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | CHRNB4 4382/4885CHRNA3 4269/4885ACVR1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.